By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – A pair of studies published online this weekend point to histone and chromatin remodeling genes as culprits in a subset of brain cancers occurring in children and young adults.
By Adam Bonislawski
With DNA-based affinity agents gaining prominence as tools for protein capture, scientists and biotech firms are exploring biomarker assays that simultaneously report both genetic and proteomic data.
The goal is to identify patient-specific rearrangements in the primary tumor, and then check for the presence of that rearrangement in the patient's blood during treatment in order to determine tumor progression and monitor therapy response.
Using microarray analyses, researchers have detected a stem cell-related gene expression pattern in an aggressive subtype of glioblastoma multiforme that involves cells expressing the transmembrane protein CD133.
The slew of PGx abstracts presented by the drug giant at the annual oncology meeting highlighted its “focused approach to cancer drug development through the identification and validation of molecular targets,” Pfizer said.